Pradeep Natarajan, M.D., M.M.Sc., FAHA, will receive the American Heart Association’s Population Research Prize during Scientific Sessions 2026, the organization announced. The meeting, scheduled for Nov. 6-9, 2026, in Chicago, is a premier global exchange of cardiovascular science. Natarajan will be recognized during the Presidential Session on Sunday, Nov. 8.
Natarajan is internationally recognized for using human genetics and data from large, diverse populations to transform the understanding and prevention of cardiovascular disease. His research has uncovered genetic mechanisms in lipid disorders, coronary artery disease and clonal hematopoiesis, while advancing polygenic risk scores and precision medicine approaches that may help identify individuals with elevated cardiovascular risk earlier in life. His discoveries have also accelerated the development of novel therapeutic targets.
“Congratulations to Dr. Pradeep Natarajan for his groundbreaking work that has redefined how human genetics and large population studies can be used to prevent cardiovascular disease,” said Manesh R. Patel, M.D., FAHA, the American Heart Association’s 2026-2027 volunteer president. “His innovative research has helped bridge genomic discovery with clinical application, advancing precision medicine while improving our understanding of cardiovascular risk across diverse populations.”
Natarajan’s most influential contributions include advancing the interpretation of whole-genome sequencing for cardiovascular disease, identifying novel genetic pathways in lipid metabolism and coronary artery disease, and developing polygenic risk prediction tools. His research has integrated genomics, multi-omics, electronic health records and large population biobanks. He has led numerous National Institutes of Health-funded investigations and his work spans international collaborations involving millions of participants.
A longtime volunteer leader with the Heart Association since 2011, Natarajan has been a member of its Data Science and Precision Medicine Committee since 2020, serving as vice chair from 2022 to 2024 and chair since 2024. He has served on the Scientific Sessions Planning Committee since 2021 and as vice chair of writing groups for three scientific statements addressing polygenic risk scores for cardiovascular disease, direct-to-consumer genetic testing for cardiovascular disease and the cardiovascular implications of clonal hematopoiesis. He was also a member of the writing committee for the 2026 Joint Clinical Practice Guideline on the Management of Dyslipidemia.
“I am honored to receive this recognition from the American Heart Association, an organization that shares my mission to improve health outcomes for those impacted by cardiovascular disease,” Natarajan said. “I have dedicated my career to discovering and understanding the drivers of cardiovascular disease using human genetics, innovative methods and interdisciplinary collaboration towards optimal cardiovascular prevention and health.”
In August 2026, Natarajan joined Amgen as vice president of global research, head of human genetics and head of the Cardiometabolic Therapeutic Area. He also serves as a professor of medicine at Harvard Medical School and a distinguished physician at Massachusetts General Hospital. He has authored or co-authored more than 330 peer-reviewed publications and has been principal investigator on several major NIH-funded studies, including an $11.2 million NIH Common Fund project on somatic mosaicism.
Additional multimedia is available on the right column of the release link. For more information, visit heart.org or stroke.org. The original release is available on www.newmediawire.com.
